about
Primary growth hormone insensitivity (Laron syndrome) and acquired hypothyroidism: a case reportMissense mutation in the transcription factor NKX2-5: a novel molecular event in the pathogenesis of thyroid dysgenesisThe good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms.Human thyroid autoantigens and proteins of Yersinia and Borrelia share amino acid sequence homology that includes binding motifs to HLA-DR molecules and T-cell receptor.Targeting the MAPK-RAS-RAF signaling pathway in cancer therapyDNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma.Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patientsMutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast.Hypercalcemia in cancer patients: pathobiology and management.Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancersThe evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.Breast cancer assessment tools and optimizing adjuvant therapy.Triple negative breast cancer: a heterogeneous subgroup defined by what it is not.RET TKI: potential role in thyroid cancers.Targeting triple negative breast cancer: is p53 the answer?Targeting the microRNA-regulating DNA damage/repair pathways in cancer.A miRNA signature associated with human metastatic medullary thyroid carcinoma.Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.Notch is a direct negative regulator of the DNA-damage response.TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.A novel von Hippel-Lindau point mutation presents as apparently sporadic pheochromocytoma.Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer.Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer.Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma.Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.Lymphocytic hypophysitis: differential diagnosis and effects of high-dose pulse steroids, followed by azathioprine, on the pituitary mass and endocrine abnormalities--report of a case and literature review.Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patientsGrowth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratificationGermline mutation of von Hippel-Lindau (VHL) gene 695 G>A (R161Q) in a patient with a peculiar phenotype with type 2C VHL syndromePhosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancerFour patients with cutaneous metastases from medullary thyroid cancer
P50
Q21202087-309FDA7E-41C0-4BCC-A758-81EF55251069Q24301402-6666B05D-E7E3-4F79-BE03-B3104CD59A5AQ34471577-6A4B045C-E69B-467C-9724-DD01BACCBDF4Q34506619-F832A2D2-DB7D-40F9-8F0C-B10E77946B63Q36278239-3762C318-23BC-4C8E-94C0-BBFC8F17D0B0Q37247163-412A2308-82A8-4370-80EE-49016DD497ADQ37311366-F531D83E-D6D3-4C16-83BC-23D54AEBA079Q37394399-E82FEF6B-A704-43AE-9DA0-E31E8C7A6117Q37454306-AE9FDE91-76D5-40A0-987F-7743CCB752F1Q37517708-2E7D82D5-C4A5-447F-951D-1AD163145CF6Q37598448-8228B7B7-E916-4AE5-9DE4-0F506964C607Q37606424-31B2FBA3-B62D-482A-B64F-BE4D9CBC5551Q37644331-9024A898-CA95-4D9F-B9E6-2989C864E0FEQ37690351-33464807-CFDB-48F3-9EE2-E62728E1496BQ37770362-968AB6C7-39B2-4C12-94B3-C7EDD7E70C34Q37803121-6A683441-CBD4-4D6D-A3A3-244C52E6C6FCQ37937916-60A09A7B-7FE0-4BA4-86D3-691D6E24B3E1Q37979656-DC119F04-9F91-42C9-B173-E781591501E6Q38074211-742BCC62-D5E6-4B11-BD94-51B3C13843BEQ38246220-484B900A-3A98-4682-A9B6-7A5A2A49056AQ38311922-04D69865-DFDB-495F-8B02-8B2068FDAD46Q38503905-CBFC16DC-E972-4B80-B56D-554C382F04ECQ38884385-05412678-5404-44EA-9156-ACF22890710BQ39030842-3D2598B6-9837-4C0D-B961-089972691096Q39779772-7EA600DC-453F-4DDE-BF2E-B20576761620Q41251561-16B4BD12-54D4-45FD-89BC-B31C00453A68Q42854034-44575E1E-5EA5-4A13-965C-610B46A6600FQ43011644-9D7C8F5E-FFC4-4AA8-827B-9F58FDE020D8Q43421516-813CF843-F8A6-4A51-B1EA-4C11ABDD0BE3Q44522795-C0D04EF9-AF08-4407-BD12-026093D24FDDQ44836546-D31D7701-795C-4B74-8A53-B1C42DA25304Q46129751-93B5E218-CA2D-4D83-AB83-74A49920813FQ46239526-960BAED2-3CE4-4E23-B933-99606D508D15Q53651538-48D113C9-CED7-475C-B58D-4019C913A5A0Q55139705-371DBF85-B61B-4172-8AA4-B56C948DFB1CQ60614470-0F9DCB0E-F380-4E6A-A92A-5641C3D2FE50Q63446762-F917184F-76F4-4E76-BC91-19945DBD40D6Q79354832-F50189DF-7ACC-4C31-ABC0-D18578CB1FFCQ81566849-97933DED-AD5B-4F47-9137-F004E928ED3DQ81693404-AA1F4595-1FAD-4F41-B399-C4F3A637FBA4
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Libero Santarpia
@ast
Libero Santarpia
@en
Libero Santarpia
@es
Libero Santarpia
@sl
type
label
Libero Santarpia
@ast
Libero Santarpia
@en
Libero Santarpia
@es
Libero Santarpia
@sl
prefLabel
Libero Santarpia
@ast
Libero Santarpia
@en
Libero Santarpia
@es
Libero Santarpia
@sl
P106
P1153
23028912000
P21
P31
P496
0000-0001-6777-1449